was a noncaseating granuloma. Fungal, bacterial, and tuberculosis stains of the tissue were all negative. Skin testing for candida and mumps was positive, but a test for tuberculosis (PPD) was negative. Results of a chest radiograph, a chest CT scan, and pulmonary function tests done after the biopsy were unremarkable. The patient's complete blood count and serum protein and calcium levels were normal, and a test for human immunodeficiency virus and a VDRL test were negative. His serum angiotensin converting enzyme (SACE) level was elevated at 95 UIL (normal 8 to 52 UIL). Findings from a full ophthalmologic examination, including slit-lamp examination and dilated fundoscopy, were normal.
A presumptive diagnosis of neurosarcoidosis was made, and the patient was given oral prednisone at 60 mg/d. Triple antituberculosis therapy and amphotericin B were also prescribed. When all cultures and serologic reports came back negative, these drugs were stopped. The patient's hypertension was controlled by sustained-release nifedipine.
With corticosteroid therapy the patient's headaches dramatically improved, and his SACE level decreased to 65 UIL. During the next several months, the patient did well. Tapering the prednisone dose, however, led to recurrence of the headaches along with blurred vision and bilateral lower extremity numbness. On a lumbar puncture, his opening pressure was elevated (45 mm of water), and his cerebral spinal fluid (CSF) glucose level was 108 mg/dL and CSF protein level was 70 mg/dL. Magnetic resonance imaging (MRI) showed the same temporo-occipital mass with new enhancement along the interhemispheric fissure above the corpus callosum. The patient's prednisone was increased to 60 mg/ d, and oral methotrexate was added as a potential corticosteroidsparing agent. The patient's symptoms again improved with this therapy.
Approximately 2 months later, again while tapering his corticosteroid therapy, the patient developed mental status changes, memory problems, and worsening bilateral lower extremity weakness. While the SACE had normalized (47 U/L) and a head MRI showed a decrease in the left temporal lobe lesion, an MRI of the cervical and thoracic spine showed patchy lesions consistent with sarcoid. An electroencephalogram showed sharp and low-wave complexes in the left temporal posterior and left frontal regions believed to be epileptiform. As a result, phenytoin was prescribed (Dilantin), the prednisone was again increased to 60 mg/d, and methotrexate was discontinued.
Since the diagnosis 3 years ago, we have been unable to taper the patient's prednisone dose below 20 mg/d because of the resulting recurrent headaches, bilateral lower extremity weakness, visual changes, and behavior changes. Azathioprine and hydroxychloroquine (plaquenil) have been added to the patient's drug regimen but have not been completely successful as corticosteroid-paring agents. His most recent head MRI, however, showed no evidence of a temporal lobe lesion and no lesions in the cervical or thoracic spine.
Literature Review
Sarcoidosis is a systemic disease most commonly affecting the lungs and lymphatic system. Sarcoidosis has a higher incidence in African-mericans and usually appears in the third or fourth decade of life. Biopsies of sarcoid lesions typically show histologic findings of noncaseating granulomas. Other causes for non caseating granu lomas that should be considered include berylliosis, syphilis, Crohn disea e, primary biliary cirrhosis, fungal . infections, and mycobacterial infections. 1 Sarcoidosis remains a diagnosis of exclusion after appropriate evaluation for the other diseases that can cause granu lomatous disease. If a clinician suspects arcoido is, patients should be examined carefully for lesions in th lymph nodes, liver, spleen, eyes, heart, parotid gland, and thyroid. In patient with sarcoidosis, 16% to 25% wi ll have skin involvement including erythema nodo urn, lupus pernio, and assorted plaques, nodules, papules, and macule .1.2 Depending on the location of lesions, skin biopsy and transbronchhllung biopsies have the best yield and lowest morbidity for diagnosis. have shown patients with neurosarcoid si are slightly younger than the expected age distribution for sarc idosis, but other studie have found n age difference between patient with arcoidosis and neuro arcoidosis.
• B
Most patients witl1 neurosarcoido is have only minimal symptoms. The most common sign is cra-N euro arcoidosis 407 nial nerve involvement including seventh facial nerve palsy. Patients can also complain of headaches or seizures. Less common signs include intracranial bleeding, hypertension, hyperprolactinemia, and diabetes insipidus. Rarely does sarcoidosis occur as a mass in the central nervous system, and in most cases patients are ultimately found to have sarcoid lesions elsewhere in the body.9-12 Our patient was somewhat unique. \Vhereas his brain mass was pathologically a sarcoid lesion, he had no evidence of sarcoidosis outside the central nervous system based on a chest radiograph, gallium scan, and chest CT. Isolated sarcoidosis of the central nervous system has been reported only a few times in the literature. 13 ,14 The diagnosis of neurosarcoidosis has improved with the advent of CT and MRI imaging. These imaging procedures have allowed for better visualization of lesions in the central nervous system. SACE levels are not helpful in the diagnosis of neurosarcoidosis. In one series, only one half of the patients with neurosarcoidosis had elevated SACE levels. S Prognosis for patients with neurosarcoidosis depends on the extent of involvement. Patients with limited facial nerve involvement usually have a good outcome. Patients with cerebral or spinal masses, hydrocephalus, or seizures tend to have a worse prognosis. 1 s, 16 Corticosteroids are the cornerstone of treatment for neurosarcoidosis. Early studies have shown good results with corticosteroids alone, but recent studies have shown patients have better outcomes when adjuvant therapies are added.
3 \Vhen corticosteroids alone fail to control symptoms and shrink lesions, other options for treatment include azathioprine,17 methotrexate, 18 cyclophosphamide,19 hydroxychloroquine, S and radiotherapy. 20 Cyclosporin has also been used with mixed results. 21 ,22 Most of these studies, however, are either anecdotal reports or have few patients in the study. In this patient temporal lobe mass and spinal lesions disappear~d with therapy, but he continues to have clinical symptoms despite adjuvant therapies.
